EP Patent

EP4093380A1 — Pharmaceutical compositions of raltegravir

Assigned to Lupin Ltd · Expires 2022-11-30 · 3y expired

What this patent protects

A solid pharmaceutical composition for oral administration comprising raltegravir or its pharmaceutical acceptable salts and pH modifying agent.

USPTO Abstract

A solid pharmaceutical composition for oral administration comprising raltegravir or its pharmaceutical acceptable salts and pH modifying agent.

Drugs covered by this patent

Patent Metadata

Patent number
EP4093380A1
Jurisdiction
EP
Classification
—
Expires
2022-11-30
Drug substance claim
No
Drug product claim
No
Assignee
Lupin Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.